A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: main beliefs (20)

Brigatinib

Description
Chemotherapy Protocol Lung Cancer Regimen Brigatinib • NSCLC – Brigatinib Indication • Brigatinib is indicated as monotherapy for the treatment of adult patients with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Brigatinib.pdf

Atezolizumab1680mg

Description
Chemotherapy Protocol LUNG CANCER Atezolizumab (1680mg 28 days) Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab1680mg.pdf

Atezolizumab

Description
Chemotherapy Protocol LUNG CANCER Atezolizumab Regimen • Lung – Atezolizumab Indication • Atezolizumab is indicated for treating previously platinum-treated locally advanced/ metastatic non
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Atezolizumab.pdf

Nivolumab ver 1 (NSCLC)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastatic squamous non
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

Cisplatin (70) Gemcitabine ver1.1

Description
Chemotherapy Protocol BLADDER CISPLATIN (70)-GEMCITABINE Regimen Bladder-Cisplatin (70)-Gemcitabine Indication First line treatment of locally advanced or metastatic urothelial
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Cisplatin-70-Gemcitabine-ver1.1.pdf

Cisplatin (35) Gemcitabine ver1.1

Description
Chemotherapy Protocol BLADDER CISPLATIN (35)-GEMCITABINE Regimen Bladder-Cisplatin (35)-Gemcitabine Indication For use in patients unable to tolerate standard cisplatin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Cisplatin-35-Gemcitabine-ver1.1.pdf

Atezolizumab(1680-28days)

Description
Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab (1680mg-28 days) Regimen • Urothelial– Atezolizumab (1680mg-28 days) Indication • This protocol was developed in response
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab1680-28days.pdf

Atezolizumab

Description
Chemotherapy Protocol GENITOURINARY CANCER Atezolizumab Regimen • Bladder – Atezolizumab Indication • The treatment of adult patients with locally advanced or metastatic urothelial carcinoma
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab.pdf

Tivozanib

Description
Chemotherapy Protocol RENAL CELL Regimen TIVOZANIB • Renal Cell - Tivozanib Indication • Patients with a confirmed histological diagnosis of renal cell carcinoma with
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Tivozanib.pdf

Everolimus-Lenvatinib

Description
Chemotherapy Protocol RENAL CELL EVEROLIMUS and LENVATINIB Regimen • Renal Cell – Everolimus-Lenvatinib Indication • Confirmed histological diagnosis of inoperable locally advanced or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Renal-cell/Everolimus-Lenvatinib.pdf
361 to 370 of 564
Previous … 35 36 37 38 39 … Next